Experts hail bladder cancer drug 'breakthrough'
Medical experts in Sheffield have hailed as a "game changer" trials of a drug that could reduce the recurrence of bladder ...
The Independent on MSN4d
‘Game changer’ immunotherapy drug could lead to increased survival rates for bladder cancer patients
The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...
Bladder cancer: Symptoms to look out for and when to see a doctor
Symptoms to look out for and when to see a doctor - There are roughly 10,000 people a year diagnosed with bladder cancer in ...
Cancer Therapy Advisor4d
Durvalumab Plus Bevacizumab and TACE: A New Standard of Care for HCC?
Adding durvalumab and bevacizumab to transarterial chemoembolization improved responses and progression-free survival.
Lung cancer drug already available on NHS could cut bladder deaths
A lung cancer drug already available on the NHS has been proven to cut bladder cancer deaths and reduce the risk of the ...
The Tab1d
University of Sheffield researchers make bladder cancer treatment ‘breakthrough’
Researchers from the University of Sheffield and Barts Cancer Institute at Queen Mary, University of London have found that ...
Targeted Oncology8d
No Improvement With Durvalumab vs Cetuximab in Advanced HNSCC
The NRG-HN004 trial showed that durvalumab did not improve outcomes vs cetuximab in locoregionally advanced head and neck ...
Most common symptom of bladder cancer to watch out for
They hope it will be approved by the Medicines and Healthcare Products Regulatory Agency to become the new standard of care.
University of Sheffield4d
Survival rates for patients with operable bladder cancer significantly improved by immunotherapy before and after surgery
A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder ...
National Institute for Health and Care Excellence2d
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer
There is a simple discount patient access scheme for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...